Global prevalence of coronavirus disease 2019 reinfection: a systematic review and meta-analysis

被引:22
作者
Ukwishaka, Joyeuse [1 ,2 ,3 ]
Ndayishimiye, Yves [3 ]
Destine, Esmeralda [3 ]
Danwang, Celestin [4 ]
Kirakoya-Samadoulougou, Fati [3 ]
机构
[1] Rwanda Biomed Ctr, Maternal Child & Community Hlth Div, Kigali, Rwanda
[2] Intrahlth Int, Kigali, Rwanda
[3] Univ Libre Bruxelles, Ecole Sante Publ, Ctr Rech Epidemiol Biostat & Rech Clin, Brussels, Belgium
[4] Clinton Hlth Access Initiat Inc, Boston, MA USA
关键词
COVID-19; Reinfection; Prevalence; SARS-COV-2; REINFECTION; COVID-19; TRANSMISSION; DIAGNOSIS;
D O I
10.1186/s12889-023-15626-7
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
BackgroundIn December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged with a high transmissibility rate and resulted in numerous negative impacts on global life. Preventive measures such as face masks, social distancing, and vaccination helped control the pandemic. Nonetheless, the emergence of SARS-CoV-2 variants, such as Omega and Delta, as well as coronavirus disease 2019 (COVID-19) reinfection, raise additional concerns. Therefore, this study aimed to determine the overall prevalence of reinfection on global and regional scales.MethodsA systematic search was conducted across three databases, PubMed, Scopus, and ProQuest Central, including all articles pertaining to COVID-19 reinfection without language restriction. After critical appraisal and qualitative synthesis of the identified relevant articles, a meta-analysis considering random effects was used to pool the studies.ResultsWe included 52 studies conducted between 2019 and 2022, with a total sample size of 3,623,655 patients. The overall prevalence of COVID-19 reinfection was 4.2% (95% confidence interval [CI]: 3.7-4.8%; n = 52), with high heterogeneity between studies. Africa had the highest prevalence of 4.7% (95% CI: 1.9-7.5%; n = 3), whereas Oceania and America had lower estimates of 0.3% (95% CI: 0.2-0.4%; n = 1) and 1% (95% CI: 0.8-1.3%; n = 7), respectively. The prevalence of reinfection in Europe and Asia was 1.2% (95% CI: 0.8-1.5%; n = 8) and 3.8% (95% CI: 3.4-4.3%; n = 43), respectively. Studies that used a combined type of specimen had the highest prevalence of 7.6% (95% CI: 5.8-9.5%; n = 15) compared with those that used oropharyngeal or nasopharyngeal swabs only that had lower estimates of 6.7% (95% CI: 4.8-8.5%; n = 8), and 3.4% (95% CI: 2.8-4.0%; n = 12) respectively.ConclusionCOVID-19 reinfection occurs with varying prevalence worldwide, with the highest occurring in Africa. Therefore, preventive measures, including vaccination, should be emphasized to ensure control of the pandemic.
引用
收藏
页数:20
相关论文
共 105 条
[1]   Post discharge positive re-tests in COVID-19: common but clinically non-significant [J].
Abdullah, Muhammad Syafiq ;
Chong, Pui Lin ;
Asli, Rosmonaliza ;
Momin, Riamiza Natalie ;
Mani, Babu Ivan ;
Metussin, Dhiya ;
Chong, Vui Heng .
INFECTIOUS DISEASES, 2020, 52 (10) :743-745
[2]   Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting [J].
Abu-Raddad, Laith J. ;
Chemaitelly, Hiam ;
Malek, Joel A. ;
Ahmed, Ayeda A. ;
Mohamoud, Yasmin A. ;
Younuskunju, Shameem ;
Ayoub, Houssein H. ;
Al Kanaani, Zaina ;
Al Khal, Abdullatif ;
Al Kuwari, Einas ;
Butt, Adeel A. ;
Coyle, Peter ;
Jeremijenko, Andrew ;
Kaleeckal, Anvar Hassan ;
Latif, Ali Nizar ;
Shaik, Riyazuddin Mohammad ;
Rahim, Hanan F. Abdul ;
Yassine, Hadi M. ;
Al Kuwari, Mohamed G. ;
Al Romaihi, Hamad Eid ;
Al-Thani, Mohamed H. ;
Bertollini, Roberto .
CLINICAL INFECTIOUS DISEASES, 2021, 73 (07) :E1830-E1840
[3]   R0 and Re of COVID-19: Can We Predict When the Pandemic Outbreak Will Be Contained? [J].
Achaiah, Nithya C. ;
Subbarajasetty, Sindhu B. ;
Shetty, Rajesh M. ;
Journal, Indian .
INDIAN JOURNAL OF CRITICAL CARE MEDICINE, 2020, 24 (11) :1125-1127
[4]  
Adams S, 2019, ANN ONCOL, V30, P405, DOI [10.1093/annonc/mdy518, 10.1093/annonc/mdy517]
[5]   COVID-19 reinfection in Liberia: Implication for improving disease surveillance [J].
Akpan, Godwin E. ;
Bawo, Luke ;
Amo-Addae, Maame ;
Kennedy, Jallah ;
Wesseh, C. Sanford ;
Whesseh, Faith ;
Adewuyi, Peter ;
Sanvee-Blebo, Lily ;
Babalola, Joseph ;
Sesay, Himiede W. W. ;
Yeabah, Trokon O. ;
Jackson, Dikena ;
Shannon, Fulton ;
Umeokonkwo, Chukwuma David ;
Nyenswah, Abraham W. ;
Macauley, Jane ;
Jallah, Wilhelmina .
PLOS ONE, 2022, 17 (03)
[6]   Effectiveness of COVID-19 diagnosis and management tools: A review [J].
Alsharif, W. ;
Qurashi, A. .
RADIOGRAPHY, 2021, 27 (02) :682-687
[7]   Protection against the Omicron Variant from Previous SARS-CoV-2 Infection [J].
Altarawneh, Heba N. ;
Chemaitelly, Hiam ;
Hasan, Mohammad R. ;
Ayoub, Houssein H. ;
Qassim, Suelen ;
AlMukdad, Sawsan ;
Coyle, Peter ;
Yassine, Hadi M. ;
Al-Khatib, Hebah A. ;
Benslimane, Fatiha M. ;
Al-Kanaani, Zaina ;
Al-Kuwari, Einas ;
Jeremijenko, Andrew ;
Kaleeckal, Anvar H. ;
Latif, Ali N. ;
Shaik, Riyazuddin M. ;
Abdul-Rahim, Hanan F. ;
Nasrallah, Gheyath K. ;
Al-Kuwari, Mohamed G. ;
Butt, Adeel A. ;
Al-Romaihi, Hamad E. ;
Al-Thani, Mohamed H. ;
Al-Khal, Abdullatif ;
Bertollini, Roberto ;
Tang, Patrick ;
Abu-Raddad, Laith J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (13) :1288-1290
[8]   Clinical characteristics of recovered COVID-19 patients with re-detectable positive RNA test [J].
An, Jianghong ;
Liao, Xuejiao ;
Xiao, Tongyang ;
Qian, Shen ;
Yuan, Jing ;
Ye, Haocheng ;
Qi, Furong ;
Shen, Chengguang ;
Wang, Lifei ;
Liu, Yang ;
Cheng, Xiaoya ;
Li, Na ;
Cai, Qingxian ;
Wang, Fang ;
Chen, Jun ;
Li, Guojun ;
Cai, Qiu'e ;
Liu, Yingxia ;
Wang, Yunfang ;
Zhang, Feng ;
Fu, Yang ;
He, Qing ;
Tan, Xiaohua ;
Liu, Lei ;
Zhang, Zheng .
ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (17)
[9]  
[Anonymous], 2022, Middle East respiratory syndrome coronavirus
[10]  
[Anonymous], 2020, SCIENS REIN UPD OCT